U S Stem Cell Inc Financials

USRM

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2022 Currency USD FYE December

This page shows U S Stem Cell Inc (USRM) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 23 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI USRM FY2022 2026-04-22

External financing is sustaining a tiny-revenue business whose high gross margins still do not produce liquidity.

By FY2022, revenue was just $82K while gross margin remained 71.0%, which suggests the core offering was not the main constraint; the business lacked the scale needed to absorb overhead and existing obligations. At the same time, financing inflow of $271K almost matched operating cash burn of -$305K, so new capital was replacing consumed cash rather than rebuilding liquidity.

Working-capital capacity was extremely thin: the current ratio stayed under 0.1x against $14.1M of current liabilities in FY2022. That means vendors, lenders, or fresh funding had to bridge normal operating needs, because internally available liquidity was not enough to cover near-term claims.

From FY2020 to FY2022, total liabilities climbed from $11.7M to $14.8M. Over the same span, shares outstanding rose from 435.6M to 634.4M, consistent with a capital structure that kept leaning on outside support while the obligation load continued to grow.

Financial Health Signals

Financial Profile 0/100

Based on FY2022 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of U S Stem Cell Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Growth

U S Stem Cell Inc's revenue declined 59.1% year-over-year, from $201K to $82K. This contraction results in a growth score of 0/100.

Liquidity

U S Stem Cell Inc's current ratio of 0.00 is below the typical benchmark, resulting in a score of 0/100. This tight liquidity could limit financial flexibility if cash inflows slow.

Piotroski F-Score Weak

1/9

U S Stem Cell Inc passes 1 of 9 financial strength tests. No profitability signals pass, 1 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$82K

YoY-59.1%

5Y CAGR-56.9%

10Y CAGR+3.0%

U S Stem Cell Inc generated $82K in revenue in fiscal year 2022. This represents a decrease of 59.1% from the prior year.

EBITDA

N/A

Net Income

N/A

EPS (Diluted)

N/A

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$5K

YoY-87.0%

5Y CAGR-65.1%

U S Stem Cell Inc held $5K in cash against $0 in long-term debt as of fiscal year 2022.

Dividends Per Share

N/A

Shares Outstanding

634M

YoY+26.0%

5Y CAGR+13.1%

U S Stem Cell Inc had 634M shares outstanding in fiscal year 2022. This represents an increase of 26.0% from the prior year.

Margins & Returns

Gross Margin

71.0%

YoY-3.0pp

5Y CAGR+5.2pp

10Y CAGR-27.2pp

U S Stem Cell Inc's gross margin was 71.0% in fiscal year 2022, indicating the percentage of revenue retained after direct costs. This is down 3.0 percentage points from the prior year.

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

Capital Allocation

R&D Spending

N/A

Share Buybacks

N/A

Capital Expenditures

N/A

USRM Income Statement

Metric	FY22	FY21	FY20	FY19	FY18	FY17
Revenue	$82K-59.1%	$201K-27.6%	$277K	N/A	$6.7M+21.4%	$5.5M
Cost of Revenue	$24K-54.3%	$52K-18.9%	$64K	N/A	$2.1M+11.9%	$1.9M
Gross Profit	$58K-60.8%	$149K-30.2%	$213K	N/A	$4.6M+26.3%	$3.6M
R&D Expenses	N/A	$0	$0-100.0%	$263-95.2%	$5K-18.1%	$7K
SG&A Expenses	N/A	N/A	N/A	N/A	$5.7M+28.4%	$4.4M
Operating Income	N/A	N/A	N/A	N/A	-$1.1M-36.4%	-$805K
Interest Expense	N/A	$1.0M+104.8%	$488K	N/A	$1.4M+125.0%	$642K
Income Tax	$0	$0	$0	$0	$0	$0
Net Income	N/A	N/A	N/A	N/A	-$2.2M+37.9%	-$3.5M
EPS (Diluted)	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'22	Q3'22	Q2'22	Q1'22	Q4'21	Q3'21	Q2'21	Q1'21
Revenue	$20K+40.2%	$14K-41.9%	$25K+5.2%	$23K-1.2%	$24K-58.8%	$57K+61.8%	$35K-58.0%	$84K
Cost of Revenue	$5K-6.5%	$5K-15.7%	$6K-14.8%	$7K-15.0%	$9K-39.2%	$14K+3.8%	$14K-11.9%	$16K
Gross Profit	$15K+67.6%	$9K-50.8%	$18K+14.4%	$16K+6.8%	$15K-65.3%	$43K+98.2%	$22K-68.4%	$69K
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	N/A	$406K	N/A	$531K	N/A	N/A	$803K+44.4%	$556K
Operating Income	N/A	-$397K	N/A	-$515K	N/A	N/A	-$781K-60.4%	-$487K
Interest Expense	N/A	$169K-3.8%	$176K+14.0%	$154K	N/A	$162K-2.7%	$167K+7.9%	$155K
Income Tax	$0	$0	$0	$0	$0	$0	$0	$0
Net Income	N/A	-$565K	N/A	N/A	N/A	N/A	N/A	-$980K
EPS (Diluted)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

USRM Balance Sheet

Metric	FY22	FY21	FY20	FY19	FY18	FY17
Total Assets	$68K+33.4%	$51K-42.1%	$88K-1.9%	$90K-95.1%	$1.8M+13.7%	$1.6M
Current Assets	$68K+33.4%	$51K-42.1%	$88K+33.0%	$66K-95.6%	$1.5M+36.6%	$1.1M
Cash & Equivalents	$5K-87.0%	$39K+112.1%	$19K	$0-100.0%	$1.4M+37.5%	$987K
Inventory	$980+149.4%	$393-92.7%	$5K-33.1%	$8K-91.3%	$93K+32.5%	$70K
Accounts Receivable	$4K+257.1%	$1K-97.8%	$54K+12.4%	$48K+167.3%	$18K-58.0%	$43K
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$14.8M+15.6%	$12.8M+9.9%	$11.7M+21.9%	$9.6M+10.0%	$8.7M0.0%	$8.7M
Current Liabilities	$14.1M+16.9%	$12.0M+11.0%	$10.8M+24.0%	$8.8M+47.9%	$5.9M-8.5%	$6.5M
Long-Term Debt	N/A	N/A	N/A	$0-100.0%	$1.3M+5.7%	$1.2M
Total Equity	-$14.7M-15.5%	-$12.8M-10.3%	-$11.6M-22.2%	-$9.5M-37.7%	-$6.9M+3.1%	-$7.1M
Retained Earnings	-$142.5M-1.9%	-$139.8M-2.4%	-$136.5M-2.2%	-$133.6M-3.0%	-$129.8M-1.7%	-$127.6M

Metric	Q4'22	Q3'22	Q2'22	Q1'22	Q4'21	Q3'21	Q2'21	Q1'21
Total Assets	$68K-60.4%	$172K+141.8%	$71K-50.1%	$142K+179.1%	$51K-37.0%	$81K-59.2%	$199K-69.0%	$641K
Current Assets	$68K-60.4%	$172K+141.8%	$71K-50.1%	$142K+179.1%	$51K-37.0%	$81K-59.2%	$199K-69.0%	$641K
Cash & Equivalents	$5K-83.0%	$30K+191.9%	$10K-28.6%	$14K-63.3%	$39K+29.9%	$30K-78.0%	$138K-68.9%	$444K
Inventory	$980+39.6%	$702+0.1%	$701+18.2%	$593+50.9%	$393-79.8%	$2K-58.6%	$5K+32.7%	$4K
Accounts Receivable	$4K+35.7%	$3K-60.4%	$8K+78.5%	$5K+272.5%	$1K-96.5%	$35K+3.0%	$34K-68.2%	$107K
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$14.8M+3.1%	$14.4M+3.2%	$13.9M+3.1%	$13.5M+5.4%	$12.8M+3.2%	$12.4M+2.8%	$12.1M+2.7%	$11.8M
Current Liabilities	$14.1M+3.3%	$13.6M+3.5%	$13.2M+3.4%	$12.7M+5.8%	$12.0M+3.5%	$11.6M+3.1%	$11.3M+3.0%	$11.0M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$14.7M-3.8%	-$14.2M-2.5%	-$13.9M-3.7%	-$13.4M-4.7%	-$12.8M-3.4%	-$12.3M-3.8%	-$11.9M-6.8%	-$11.1M
Retained Earnings	-$142.5M-0.4%	-$142.0M-0.4%	-$141.4M-0.4%	-$140.8M-0.7%	-$139.8M-0.5%	-$139.2M-0.5%	-$138.5M-0.7%	-$137.5M

USRM Cash Flow Statement

Metric	FY22	FY21	FY20	FY19	FY18	FY17
Operating Cash Flow	-$305K	N/A	-$479K	N/A	$602K-51.1%	$1.2M
Capital Expenditures	N/A	N/A	N/A	N/A	$0-100.0%	$1K
Free Cash Flow	N/A	N/A	N/A	N/A	$602K-51.0%	$1.2M
Investing Cash Flow	N/A	N/A	$0-100.0%	$167K-46.5%	$312K-56.9%	$724K
Financing Cash Flow	$271K	N/A	$497K+258.9%	-$313K+42.4%	-$544K+56.1%	-$1.2M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	$0

Metric	Q4'22	Q3'22	Q2'22	Q1'22	Q4'21	Q3'21	Q2'21	Q1'21
Operating Cash Flow	-$43K+33.4%	-$65K+51.5%	-$133K-108.9%	-$64K+70.6%	-$217K-5.2%	-$206K+35.2%	-$318K-0.1%	-$318K
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	$18K-78.7%	$85K-34.6%	$129K+232.2%	$39K-82.8%	$226K+129.5%	$98K+750.2%	$12K-98.4%	$743K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

USRM Financial Ratios

Metric	FY22	FY21	FY20	FY19	FY18	FY17
Gross Margin	71.0%-3.0pp	74.1%-2.8pp	76.9%	N/A	68.5%+2.7pp	65.8%
Operating Margin	N/A	N/A	N/A	N/A	-16.4%-1.8pp	-14.6%
Net Margin	N/A	N/A	N/A	N/A	-32.2%+30.8pp	-63.1%
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	N/A	N/A	N/A	N/A	-118.9%+99.0pp	-217.9%
Current Ratio	0.000.0	0.000.0	0.010.0	0.01-0.2	0.25+0.1	0.17
Debt-to-Equity	-1.000.0	-1.000.0	-1.01-1.0	0.00+0.2	-0.19-0.0	-0.17
FCF Margin	N/A	N/A	N/A	N/A	9.0%-13.3pp	22.3%

Metric	Q4'22	Q3'22	Q2'22	Q1'22	Q4'21	Q3'21	Q2'21	Q1'21
Gross Margin	75.4%+12.3pp	63.0%-11.5pp	74.5%+6.0pp	68.5%+5.1pp	63.4%-11.8pp	75.2%+13.8pp	61.4%-20.2pp	81.6%
Operating Margin	N/A	-2783.6%	N/A	-2207.8%	N/A	N/A	-2204.2%-1626.8pp	-577.3%
Net Margin	N/A	-3968.6%	N/A	N/A	N/A	N/A	N/A	-1161.1%
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	N/A	-328.9%	N/A	N/A	N/A	N/A	N/A	-152.8%
Current Ratio	0.000.0	0.010.0	0.010.0	0.010.0	0.000.0	0.01-0.0	0.02-0.0	0.06
Debt-to-Equity	-1.000.0	-1.010.0	-1.010.0	-1.01	N/A	-1.01+0.0	-1.02+0.0	-1.06
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Note: Shareholder equity is negative (-$14.7M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.00), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Reneuron Group RNUGF

$63K

Syros Pharmaceut SYRS

$3.1M

Aridis Pharmaceuticals Inc ARDS

$9K

Adhera Therapeutics Inc ATRX

$72K

GB Sciences GBLX

$81K

Frequently Asked Questions

What is U S Stem Cell Inc's annual revenue?

U S Stem Cell Inc (USRM) reported $82K in total revenue for fiscal year 2022. This represents a -59.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is U S Stem Cell Inc's revenue growing?

U S Stem Cell Inc (USRM) revenue declined by 59.1% year-over-year, from $201K to $82K in fiscal year 2022.

What is U S Stem Cell Inc's gross margin?

U S Stem Cell Inc (USRM) had a gross margin of 71.0% in fiscal year 2022, indicating the percentage of revenue retained after direct costs of goods sold.

What is U S Stem Cell Inc's operating cash flow?

U S Stem Cell Inc (USRM) generated -$305K in operating cash flow during fiscal year 2022, representing cash generated from core business activities.

What are U S Stem Cell Inc's total assets?

U S Stem Cell Inc (USRM) had $68K in total assets as of fiscal year 2022, including both current and long-term assets.

How many shares does U S Stem Cell Inc have outstanding?

U S Stem Cell Inc (USRM) had 634M shares outstanding as of fiscal year 2022.

What is U S Stem Cell Inc's current ratio?

U S Stem Cell Inc (USRM) had a current ratio of 0.00 as of fiscal year 2022, which is below 1.0, which may suggest potential liquidity concerns.

What is U S Stem Cell Inc's debt-to-equity ratio?

U S Stem Cell Inc (USRM) had a debt-to-equity ratio of -1.00 as of fiscal year 2022, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is U S Stem Cell Inc's cash runway?

Based on fiscal year 2022 data, U S Stem Cell Inc (USRM) had $5K in cash against an annual operating cash burn of $305K. This gives an estimated cash runway of approximately 0 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Why is U S Stem Cell Inc's debt-to-equity ratio negative or unusual?

U S Stem Cell Inc (USRM) has negative shareholder equity of -$14.7M as of fiscal year 2022, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is U S Stem Cell Inc's Piotroski F-Score?

U S Stem Cell Inc (USRM) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

How financially healthy is U S Stem Cell Inc?

U S Stem Cell Inc (USRM) scores 0 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.